Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ Государственный научный центр социальной и судебной психиатрии им. В.П.Сербского Минздрава России
Список исп. литературыСкрыть список 1. Арушанян Э.Б., Байда (Мастягина) О.А., Мастягин С.С. Эксперим. и клин. фармакология. 2006; 69 (1): 21–3. 2. Арушанян Э.Б. Изучение психотропной активности гормона эпифиза мелатонина – оригинальное направление наших исследований. Эксперим. и клин. фармакология. 2007; 70 (6): 55–60. 3. Арушанян Э.Б., Бейер Э.В. Журн. высшей нервной деятельности. 1998; 48 (6): 1065–71. 4. Арушанян Э.Б. Успехи физиол. наук. 1996; 27 (3): 31–50. 5. Бобров А.С., Петрунько О.В., Хамарханова А.А., Швецова А.В. Клинические предикторы реакции на терапию Вальдоксаном при умеренной и тяжелой депрессии. Журн. неврол. и психиатр. 2010; 110 (9): 14. 6. Иванов С.В. Вальдоксан (агомелатин) при терапии умеренных и тяжелых депрессий непсихотического уровня в амбулаторной и госпитальной практике (результаты Российского многоцентрового исследования ХРОНОС). Психиатр. и психофармакотер. 2009; 6: 14–7. 7. Иванов С.В. Вальдоксан в терапии биполярной депрессии: результаты российского многоцентрового натуралистического исследования ХРОНОС. Обозрен. психиатрии и мед. психологии им. Бехтерева. 2011; 2. 8. Марачев М.П. Эффективность агомелатина при терапии атипичной депрессии. Журн. психиатр. и психофармакотер. 2012; 3: 25–30. 9. Мосолов С.Н. Эффективность и переносимость агомелатина при депрессивных состояниях в рамках рекуррентной депрессии и биполярного расстройства: доклад. Вторая Франко-Российская встреча. Париж, 2011. 10. Ованесов К.Б., Ованесова И.М., Арушанян Э.Б. Эксперим. и клин. фармакология. 2006; 69 (6): 17–9. 11. Результаты Всероссийской переписи населения 2010. http://www.perepis-2010.ru 12. Смулевич А.Б., Дубницкая Э.Б. Тревожные депрессии. Мед. газета. 2004; 2. 13. Смулевич А.Б., Андрющенко А.В., Бескова Д.А. Терапия непсихотических депрессий антидепрессантом агомелатином (Вальдоксан): результаты наблюдательного многоцентрового исследования РИТМ. Психиатр. и психофармакотер. 2010; 4: 4–11. 14. Borjigin J, Li X, Snyder SH. The pineal gland and melatonin: molecular and pharmacologic regulation. Ann Rev Pharmacol Toxicol 1999; 39: 53–65. 15. Bristow LJ, O’Connor D, Watts R et al. Evidence for accelerated desensitisation of 5HT2C-receptors following combined treatment with fluoxetine and the 5HT1A-receptor antagonist. WAY100, 635 in the rat. Neuropharmacol 2000; 39: 1222–36. 16. Casacalenda N, Boulenger JP. Pharmacologic treatment effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications. Can J Psychiat 1998; 43: 722–30. 17. Cervo L, Samanin R. 5HT1A-receptor full and partial agonists and 5HT1C (but not 5-HT3) receptor antagonists increase rates of punished responding in rats. Pharmacol Biochem Behav 1995; 52: 671–6. 18. Das S, Tecott L. Diminished anxiety-like responses in 5HT2C-receptor mutant mice. Soc Neurosci Abstr 1996; 22: 811–2. 19. Dekeyne A, Brocco M, Adhumeau A et al. The selective serotonin 5HT1A-receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialy sate levels of 5-HT in the dorsal hippocampus of freely-moving rats: a comparison with other anxiolytic agents. Psychopharmacol 2000; 152: 55–66. 20. Dekeyne A, Denorme B, Monneyron S, Millan MJ. Citalopram reduces social interaction in rats by activation of serotonin (5-HT)2 Creceptors. Neuropharmacol 2000; 39: 1114–7. 21. Fava M, Rush AJ, Alpert JE et al. Difference in treatment outcome in outpatients with anxious vs nonanxious depression: a STAR*D report. Am J Psychiat 2008; 165: 342–51. 22. Fava M, Rush AJ, Alpert JE et al. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiat 2006; 51: 823–35. 23. Fawcett J, Barkin RL. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. Int Clin Psychopharmacol 2003; 18: 203–10. 24. Golombek DA, Martini M, Cardinali DP. Melatonin as an anxiolytic in rats: time dependence and interaction with the central GABAergic system. Eur J Pharmacol 1993; 237: 231–6. 25. Golombek DA, Pevet P, Cardinali DP. Melatonin effects on behavior: possible mediation by the central GABAergic system. Neurosci Biobehav Res 1996; 20: 403–12. 26. Griebel G, Perrault G, Sanger DJ. A comparative study of the effects of selective and non-selective 5HT2-receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacol 1997; 36: 793–802. 27. Guardiola-Lemaitre B, Lenegre A, Porsolt RD. Combined effects of diazepam and melatonin in two tests for anxiolytic activity in the mouse. Pharmacol Biochem Behav 1992; 41: 405. 28. Hale A, Corral RM, Mencacci C et al. Superior antidepressant efficacy results of agomelatine vs fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol 2010; 25: 305–14. 29. Heisler LK, Zhou L, Bajwa P et al. Serotonin 5-HT2C-receptors regulate anxiety-like behavior. Gen Brain Behav 2007; 6 (5): 491–6. 30. Kasper S, Hajak G, Wulff K et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with Sertraline. J Clin Psychiat 2010; 71: 109–20. 31. Katzow JJ, Hsu DJ, Ghaemi SN. The bipolar spectrum: a clinical perspective. Bipolar Disord Vol 2003; 5 (6): 436–42. 32. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatments of major depressive disorder. Eur Neuropsychopharmacol 2006; 16: 93–100. 33. Kennett GA, Wood MD, Bright F et al. In vitro and in vivo profile of SB 206553, a potent 5HT2C/5-HT2B-receptor antagonist with anxiolytic-like properties. Br J Pharmacol 1996; 117: 427–34. 34. Kennett GA, Wood MD, Bright F et al. SB 242084, a selective and brain penetrant 5-HT2C-receptor antagonist. Neuropharmacol 1997; 36: 609–20. 35. Kopp C, Vogel E, Rettori MC et al. Effects of melatonin on neophobic responses in different strains in mice. Pharmacol Biochem Behav 1999; 63: 521–6. 36. Kopp C, Vogel E, Rettori MC et al. Anxiolytic-like properties of melatonin receptor agonists in mice: involvement of MT1 and/or MT2-receptors in the regulation of emotional responsiveness. Neuropharmacol 2000; 39: 1865–71. 37. Kopp C, Vogel E, Rettori MC et al. Antagonistic effects of S22153, a new MT1- and MT2-receptor ligand, on the neophobia-reducing properties of melatonin in BALB/c mice. Pharmacol Biochem Behav 1999; 64: 131–6. 38. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiat 2007; 68: 1723–32. 39. Loo H, Hale A, D’haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239–47. 40. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol 2003; 70: 53–244. 41. Millan MJ, Brocco M. The Vogel conflict test: procedural aspects, g-aminobutyric acid, glutamate and monoamines. Eur J Pharmacol 2003; 463: 67–96. 42. Millan MJ, Brocco M, Gobert A et al. A Anxiolytic properties of the selective, non-peptidergic CRF1-antagonists, CP 154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacol 2001; 25: 585–600. 43. Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5HT2C-receptor blockade. Psychopharmacol Berl 2005; 177 (4): 448–58. 44. Millan MJ, Gobert A, Lejeune F et al. The novel melatonin agonist, agomelatine (S20098), is an antagonist at 5-hydroxytryptamine 2C-receptors, blockade of which enhances the activity of front cortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954–64. 45. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007; 22 (5): 283–29. 46. Naguib M, Samarkandi AH. The comparative dose – response effects of melatonin and midazolam for premedication of adult patients: a double-blinded, placebo-controlled study. Anesth Analg 2000; 91: 473–9. 47. Nava F, Carta G. Melatonin reduces anxiety induced by lipopolysaccharide in the rat. Neurosci Lett 2001; 307: 57–60. 48. Niles L. Melatonin interaction with the benzodiazepine-GABA receptor complex in the CNS. Adv Exp Med Biol 1991; 294: 267–77. 49. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2-receptor agonist with 5HT2C-antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10: 661–73. 50. Papp M, Litwa E, Gruca P. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol 2006; 17 (1): 9–18. 51. Pierrefiche G, Zerbib R, Laborit H. Anxiolytic activity of melatonin in mice: involvement of benzodiazepine receptors. Res Commun Chem Pathol Pharmacol 1993; 82: 131–42. 52. Rihmer Z, Szadoczky E, Furedi J et al. Anxiety disorders comorbidity in bipolar I, bipolar II and unipolar major depression: results from a population-based study in Hungary. J Affect Dis 2001; 67 (1): 175–9. 53. Rocha B, Rigo M, Di Scala G et al. Chronicmianserin or eltoprazine treatment in rats: effects on the elevated plus-maze test and on limbic 5HT2C-receptor levels. Eur J Pharmacol 1994; 262: 125–31. 54. Schosser A, Serretti A, Souery D et al. European Group for the study of Resistant Depression (GSRD). Where have we gone so far: Review of clinical and genetic findings. Eur Neuropsychopharmacol 2012; 22 (7): 453–68. 55. Stein DJ, Ahokas AA, Alabrran C et al. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiat 2012; 73 (7): 1002–8. 56. Stein DJ, Ahokas AA, Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28: 561–6. 57. Stein DJ, Hollander E. Anxiety disorders comorbid with depression: social anxiety disorder, post-traumatic stress disorder, generalized anxiety disorder and obsessive-compulsive disorder. Martin Dunitz. London 2002. 58. Stein DJ, Picarel-Blanchot F, Kennedy SH. Efficacy of novel antidepressant agomelatine for anxiety symptoms in major depresson. Hum Psychopharmacol Clin Exp 2013; 28: 151–9.